Genmab has formed a bispecific antibody collaboration with Novartis that is potentially worth up to US$175 M plus research funding and royalties. In return for US$2 M upfront, Genmab will create panels of bispecific antibodies to two undisclosed disease target combinations selected by Novartis using its DuoBody™ technology. The deal is the latest in a string of partnerships focused on the development of next-generation antibody therapeutics.